Currently, oral GnRH antagonists, including elagolix and relugolix, have been approved for endometriosis by FDA [10] (https://www.contemporaryobgyn.net/view/fda-approves-myfembree-for-endometriosis-pain), while treating EAP with Linzagolix and ASP1707 has being evaluated in ongoing clinical trials [11, 12]. The gene discussed is GNRH1; the disease is endometriosis.